Clinical trial
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
NCT00449748 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00449748 |
|---|---|
| Title | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis |
| Official title | Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Mastocytosis |
| Intervention type | Drug |
| Interventions | RAD001 (Everolimus) |
| Enrollment | 10 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Mar 21, 2007 |
| Last update posted | May 1, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: